Moderna’s Surge Hides Financial Woes | Business and Finance News

Moderna’s stock soars over 46% in six months, hitting $63, fueled by strong quarterly results—but analysts warn caution: revenue and earnings have plunged 4% and 46% annually for five years, free cash flow turned negative, and the long-term trend signals financial strain, making it a risky bet compared to brighter alternatives. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/156d625b8c8ea3b5